Literature DB >> 10843826

Relationship of serum C3 to fasting insulin, risk factors and previous ischaemic events in middle-aged men.

A Muscari1, G Massarelli, L Bastagli, G Poggiopollini, V Tomassetti, G Drago, C Martignani, P Pacilli, P Boni, P Puddu.   

Abstract

AIMS: Serum C3 is a powerful indicator of the risk of myocardial infarction, which correlates with body mass index, serum lipids and blood pressure. This study was performed to ascertain whether such correlations may be explained by an association of C3 with fasting insulin, and to assess comparatively the relationships of C3 and traditional risk factors to previous myocardial infarction. METHODS AND
RESULTS: The fasting levels of C3, insulin, and the main risk factors were evaluated in 1090 unselected men aged 55-64 years, including 129 cases of previous ischaemic events (51 myocardial infarctions). In multivariate analysis C3 was associated with insulin (r=0.27, P<0.0001), cholesterol (r=0.18, P<0.0001), body mass index (r=0.13, P<0.0001), glucose (r=0.12, P=0.0001), systolic blood pressure (r=0.10, P<0.001), triglycerides (r=0.09, P<0.01) and HDL-cholesterol (r=-0.06, P<0.05). These variables explained 31% of the total C3 variance. Alcohol consumption and physical activity correlated inversely with C3, while no correlation was found with smoking and family history of myocardial infarction. C3 was associated with previous myocardial infarction and stroke, but not with angina pectoris and peripheral arterial disease. In logistic regression the variables associated with previous myocardial infarction were C3 (P=0.011), family history of myocardial infarction (P=0.018), ex-smoker status (P=0.020), age (P=0.025), glucose (P=0.028) and HDL-cholesterol (P=0.051, inverse relationship).
CONCLUSIONS: The association of C3 with myocardial infarction persists retrospectively, and is more significant than any other association of traditional risk factors with previous myocardial infarction. Of the many variables associated with C3, fasting insulin is its main covariate, which suggests that C3 is a marker of a pro-atherogenic metabolic imbalance partly coinciding with insulin resistance. Copyright 2000 The European Society of Cardiology.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10843826     DOI: 10.1053/euhj.1999.2013

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  32 in total

1.  Chylomicron accelerates C3 tick-over by regulating the role of factor H, leading to overproduction of acylation stimulating protein.

Authors:  Takayuki Fujita; Takayuki Fujioka; Tetsuo Murakami; Atsushi Satomura; Yoshinobu Fuke; Koichi Matsumoto
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

Review 2.  Candidate-based proteomics in the search for biomarkers of cardiovascular disease.

Authors:  Leigh Anderson
Journal:  J Physiol       Date:  2004-12-20       Impact factor: 5.182

3.  Effect of hormone replacement therapy on serum complement (C3, C4) and immunoglobulin (IgG, IgM) levels in post-menopausal women.

Authors:  Yi Liu; Liqun LV
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-02

4.  Serum complements and heart fatty acid binding protein in Bangladeshi patients with acute myocardial infarction.

Authors:  Nayareen Akhtar; Abu Taher; Rezwanur Rahman; Ashesh Kumar Chowdhury
Journal:  Heart Asia       Date:  2012-09-26

5.  The mannose-binding lectin pathway is a significant contributor to reperfusion injury in the type 2 diabetic heart.

Authors:  Laura R La Bonte; Betsy Dokken; Grace Davis-Gorman; Gregory L Stahl; Paul F McDonagh
Journal:  Diab Vasc Dis Res       Date:  2009-07       Impact factor: 3.291

Review 6.  High density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation, and atherothrombosis.

Authors:  Scott M Gordon; Alan T Remaley
Journal:  Atherosclerosis       Date:  2016-11-16       Impact factor: 5.162

Review 7.  Lipaemia, inflammation and atherosclerosis: novel opportunities in the understanding and treatment of atherosclerosis.

Authors:  Antonie J H H M van Oostrom; Jeroen van Wijk; Manuel Castro Cabezas
Journal:  Drugs       Date:  2004       Impact factor: 9.546

8.  Peroxisome proliferator-activated receptor α positively regulates complement C3 expression but inhibits tumor necrosis factor α-mediated activation of C3 gene in mammalian hepatic-derived cells.

Authors:  Denis A Mogilenko; Igor V Kudriavtsev; Vladimir S Shavva; Ella B Dizhe; Ekaterina G Vilenskaya; Alexander M Efremov; Andrej P Perevozchikov; Sergey V Orlov
Journal:  J Biol Chem       Date:  2012-11-20       Impact factor: 5.157

9.  Modified low density lipoprotein stimulates complement C3 expression and secretion via liver X receptor and Toll-like receptor 4 activation in human macrophages.

Authors:  Denis A Mogilenko; Igor V Kudriavtsev; Andrey S Trulioff; Vladimir S Shavva; Ella B Dizhe; Boris V Missyul; Alexander V Zhakhov; Alexander M Ischenko; Andrej P Perevozchikov; Sergey V Orlov
Journal:  J Biol Chem       Date:  2011-12-22       Impact factor: 5.157

10.  Anticomplement therapy.

Authors:  Prathit A Kulkarni; Vahid Afshar-Kharghan
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.